Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

02/19/2020 | 08:46am EDT

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi.

The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

'Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease,' said BARDA Director Rick A. Bright, Ph.D. 'Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks.'

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing manufacturing capacity for recombinant influenza vaccine in the United States, in accordance with a presidential executive order to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entry website for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA).

BARDA also opened an easy broad agency announcement, an EZ-BAA, specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures - vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVe brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security.


Tel: 202-205-8117

Email: asprmedia@hhs.gov

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about SANOFI
06/22EUROPE : European shares propped up by commodities, Powell speech in focus
06/22GLOBAL MARKETS LIVE : Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resour..
06/22Today on Wall Street: The investor dilemma
06/22SANOFIá : Translate Bio Launch Phase 1 Study For Influenza Vaccine
06/22SANOFIá : Translate Bio Start Phase 1 Study to Test Influenza Vaccine
06/22Sanofi, Translate Bio Start Trial Evaluating Flu Vaccine
06/22European shares propped up by commodities, Powell speech in focus
06/21MODERNAá : WHO setting up hub to make COVID-19 vaccines in South Africa
06/21MODERNAá : WHO setting up hub to make COVID-19 vaccines in South Africa
06/18TG THERAPEUTICSá : Says Multiple Sclerosis Drug 'Well Tolerated' in Phase 3 Tria..
More news
Sales 2021 36 978 M 44 121 M 44 121 M
Net income 2021 5 912 M 7 054 M 7 054 M
Net Debt 2021 7 100 M 8 471 M 8 471 M
P/E ratio 2021 18,6x
Yield 2021 3,74%
Capitalization 109 B 130 B 130 B
EV / Sales 2021 3,14x
EV / Sales 2022 2,91x
Nbr of Employees 99 412
Free-Float 88,3%
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 87,56 €
Average target price 101,75 €
Spread / Average Target 16,2%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI10.70%130 154
JOHNSON & JOHNSON3.34%428 269
ROCHE HOLDING AG10.19%321 632
PFIZER, INC.6.09%218 590
NOVARTIS AG1.55%207 926
ABBVIE INC.6.39%201 349